Eli Lilly stock has soared 125% in the past year due to strong revenue growth

From Nasdaq: 2024-04-02 05:10:00

Eli Lilly (NYSE: LLY) has seen its stock soar 125% in the past year, making it a top growth stock on the S&P 500. The company’s weight loss drugs, Mounjaro and Zepbound, are driving revenue gains with impressive sales numbers.

Lilly’s diverse product portfolio includes new and growth products that are contributing to revenue growth. Despite some facing patent expiration, Lilly’s broad range of drugs generated a 28% increase in revenue in the most recent quarter.

With its weight loss drugs, Mounjaro and Zepbound, Lilly is dominating in a lucrative market. Demand for these drugs is skyrocketing, with projections that the global weight loss drug market could reach $100 billion by 2030.

Although Lilly’s stock trades at a high valuation, the company’s long-term growth potential, especially in the weight loss market, indicates it may still be a solid investment opportunity. The company’s research and development efforts could lead to even more successful products in the future.



Read more at Nasdaq: Is It Too Late to Buy Eli Lilly Stock?